Guidance for manufacturers of artificial heart valves. It outlines specific scenarios that should be considered when determining if an incident is reportable.
Similar Posts
National assessment procedure for medicines
Guidance on the MHRA’s national assessment procedure for marketing authorisation applications.
Class 3 Medicines Recall: Sun Pharmaceutical Industries Limited, Fingolimod SUN 0.5mg hard capsules, EL(25)A/49
Sun Pharma UK Limited is conducting a precautionary recall of a single batch of Fingolimod SUN 0.5 mg hard capsules due to reports of capsule breakage on removing from the blister. No other batches of Fingolimod SUN 0.5mg hard capsules are impacted.
MHRA crackdown on illegal ‘Botox’ after victims left seriously ill
More than 40 people hospitalised following suspected use of unlicensed botulinum toxin products.
First major overhaul of medical device regulation comes into force across Great Britain
New Post-Market Surveillance (PMS) regulations have taken effect across Great Britain, requiring medical device manufacturers to proactively monitor the safety and performance of their products once on the market.
Isotretinoin: an expert review of suspected psychiatric and sexual side effects
The review of the safety of isotretinoin has concluded.
MHRA Safety Roundup: September 2025
Summary of the latest safety advice for medicines and medical device users